| abstract |
The compounds of the present disclosure are fused pyrimidine ring compounds of formula (I) as adenosine receptor antagonists, tautomers, polymorphs, stereoisomers, prodrugs, solvates, or pharmaceutically acceptable salts thereof. , Regarding. These synthetic methods are also disclosed. |